-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The net result for the period of deducting operating expenses from operating revenues.
-
Summary
-
SAB Biotherapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from Q1 2021 to Q2 2024.
- SAB Biotherapeutics, Inc. Operating Income (Loss) for the quarter ending June 30, 2024 was -$10.2M, a 57.5% decline year-over-year.
- SAB Biotherapeutics, Inc. Operating Income (Loss) for the twelve months ending June 30, 2024 was -$45.8M, a 55% decline year-over-year.
- SAB Biotherapeutics, Inc. annual Operating Income (Loss) for 2023 was -$38.1M, a 31.7% decline from 2022.
- SAB Biotherapeutics, Inc. annual Operating Income (Loss) for 2022 was -$28.9M, a 116% decline from 2021.
- SAB Biotherapeutics, Inc. annual Operating Income (Loss) for 2021 was -$13.4M, a 165% decline from 2020.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Growth (%)